Omid Hamid

Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC).

Patrick Schöffski, Keith Steele, J. Nemunaitis, 2015 .

Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAFV600- mutated melanoma (BRIM7)

Antoni Ribas, Jill Fredrickson, Omid Hamid, 2014, Journal of Translational Medicine.

Cancer Immunotherapy Principles and Practice

Ke Liu, Pedro Romero, Patricia A. Young, 2018 .

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

Henrik Schmidt, Johan Hansson, Scott D Chasalow, 2011, Journal of Translational Medicine.

Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.

Jedd D. Wolchok, Antoni Ribas, Richard F. Kefford, 2016 .

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

Antoni Ribas, Caroline Robert, Anthony M Joshua, 2013, The New England journal of medicine.

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.

Dirk Schadendorf, Alessandro Testori, Axel Hauschild, 2014, The Lancet. Oncology.

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Antoni Ribas, Caroline Robert, Anthony M Joshua, 2014, The Lancet.

An immune-active tumor microenvironment favors clinical response to ipilimumab

Rui-Ru Ji, Nathan O. Siemers, Henrik Schmidt, 2012, Cancer Immunology, Immunotherapy.

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.

Wei Zhou, Dirk Schadendorf, Reinhard Dummer, 2015, The Lancet. Oncology.

Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.

Jeffrey Weber, Keith T Flaherty, Zeynep Eroglu, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

Axel Hoos, Jedd D. Wolchok, J. Wolchok, 2009, Clinical Cancer Research.